• 生物活性

靶点及简介 ：

Daratumumab (Anti-Human CD38) 是首创的特异性抗 CD38 单克隆抗体。Daratumumab 具有抗多发性骨髓瘤(MM) 的作用。Daratumumab 损伤了 MM 细胞的粘附，从而增加了 MM 对蛋白酶体抑制的敏感性。

Daratumumab (anti-CD38) 是一种针对CD38的重组单克隆抗体。Daratumumab 是一种研究性的抗癌药物，适用于治疗多发性骨髓瘤的成年患者。MW =145.4 kDa。

Daratumumab是一种直接靶向CD38的IgG1k单克隆抗体,适用于人源或免疫缺陷型小鼠。CD38 is overexpressed in multiple myeloma cells. Daratumumab binds to CD38, causing cells to apoptose via antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity.

• 验证及参考文献

验证：

参考文献：

[1] Matas-Cespedes A, et al. Clin Cancer Res. The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia.

[2] Lokhorst HM, et al. N Engl J Med. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

• 溶解度及制备方案
  

  Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
  1 mM	0.0069 mL	0.0344 mL	0.0688 mL
  5 mM	0.0014 mL	0.0069 mL	0.0138 mL
  10 mM	0.0007 mL	0.0034 mL	0.0069 mL

  
  
  关键词：Daratumumab(anti-CD38),Darzalex,达雷木单抗, 达雷妥尤单抗，Daratumumab, DARA, Daratumumab供应商, 购买Daratumumab, Daratumumab溶解度, Daratumumab结构式